Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
Identifieur interne : 000D22 ( Main/Exploration ); précédent : 000D21; suivant : 000D23Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
Auteurs : R. San-Juan [Espagne] ; O. Manuel [Suisse] ; H H Hirsch [Suisse] ; M. Fernández-Ruiz [Espagne] ; F. L Pez-Medrano [Espagne] ; P. Comoli [Italie] ; S. Caillard [France] ; P. Grossi [Italie] ; J M Aguado [Espagne]Source :
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [ 1469-0691 ] ; 2015.
Descripteurs français
- KwdFr :
- Charge virale (MeSH), Enquêtes et questionnaires (MeSH), Europe (MeSH), Humains (MeSH), Immunosuppresseurs (administration et posologie), Infections à virus Epstein-Barr (complications), Infections à virus Epstein-Barr (diagnostic), Infections à virus Epstein-Barr (prévention et contrôle), Infections à virus Epstein-Barr (thérapie), Receveurs de transplantation (MeSH), Rituximab (administration et posologie), Syndromes lymphoprolifératifs (diagnostic), Syndromes lymphoprolifératifs (prévention et contrôle), Syndromes lymphoprolifératifs (thérapie), Sérine-thréonine kinases TOR (antagonistes et inhibiteurs), Tomodensitométrie (MeSH), Tomographie par émission de positons (MeSH), Transplantation d'organe (MeSH), Virémie (diagnostic), Études transversales (MeSH).
- MESH :
- administration et posologie : Immunosuppresseurs, Rituximab.
- antagonistes et inhibiteurs : Sérine-thréonine kinases TOR.
- diagnostic : Infections à virus Epstein-Barr, Syndromes lymphoprolifératifs, Virémie.
- prévention et contrôle : Infections à virus Epstein-Barr, Syndromes lymphoprolifératifs.
- thérapie : Infections à virus Epstein-Barr, Syndromes lymphoprolifératifs.
- Charge virale, Enquêtes et questionnaires, Europe, Humains, Infections à virus Epstein-Barr, Receveurs de transplantation, Tomodensitométrie, Tomographie par émission de positons, Transplantation d'organe, Études transversales.
English descriptors
- KwdEn :
- Cross-Sectional Studies (MeSH), Epstein-Barr Virus Infections (complications), Epstein-Barr Virus Infections (diagnosis), Epstein-Barr Virus Infections (prevention & control), Epstein-Barr Virus Infections (therapy), Europe (MeSH), Humans (MeSH), Immunosuppressive Agents (administration & dosage), Lymphoproliferative Disorders (diagnosis), Lymphoproliferative Disorders (prevention & control), Lymphoproliferative Disorders (therapy), Organ Transplantation (MeSH), Positron-Emission Tomography (MeSH), Rituximab (administration & dosage), Surveys and Questionnaires (MeSH), TOR Serine-Threonine Kinases (antagonists & inhibitors), Tomography, X-Ray Computed (MeSH), Transplant Recipients (MeSH), Viral Load (MeSH), Viremia (diagnosis).
- MESH :
- chemical , administration & dosage : Immunosuppressive Agents, Rituximab.
- chemical , antagonists & inhibitors : TOR Serine-Threonine Kinases.
- geographic : Europe.
- complications : Epstein-Barr Virus Infections.
- diagnosis : Epstein-Barr Virus Infections, Lymphoproliferative Disorders, Viremia.
- prevention & control : Epstein-Barr Virus Infections, Lymphoproliferative Disorders.
- therapy : Epstein-Barr Virus Infections, Lymphoproliferative Disorders.
- Cross-Sectional Studies, Humans, Organ Transplantation, Positron-Emission Tomography, Surveys and Questionnaires, Tomography, X-Ray Computed, Transplant Recipients, Viral Load.
Abstract
There is limited clinical evidence on the utility of the monitoring of Epstein-Barr virus (EBV) DNAemia in the pre-emptive management of post-transplant lymphoproliferative disease (PTLD) in solid organ transplant (SOT) recipients. We investigated current preventive measures against EBV-related PTLD through a web-based questionnaire sent to 669 SOT programmes in 35 European countries. This study was performed on behalf of the ESGICH study group from the European Society of Clinical Microbiology and Infectious Diseases. A total of 71 SOT programmes from 15 European countries participated in the study. EBV serostatus of the recipient is routinely obtained in 69/71 centres (97%) and 64 (90%) have access to EBV DNAemia assays. EBV monitoring is routinely used in 85.9% of the programmes and 77.4% reported performing pre-emptive treatment for patients with significant EBV DNAemia levels. Pre-emptive treatment for EBV DNAemia included reduction of immunosuppression in 50.9%, switch to mammalian target of rapamycin inhibitors in 30.9%, and use of rituximab in 14.5% of programmes. Imaging by whole-body 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) is used in 60.9% of centres to rule out PTLD and complemented computer tomography is used in 50%. In 10.9% of centres, FDG-PET is included in the first-line diagnostic workup in patients with high-risk EBV DNAemia. Despite the lack of definitive evidence, EBV load measurements are frequently used in Europe to guide diagnostic workup and pre-emptive reduction of immunosuppression. We need prospective and controlled studies to define the impact of EBV monitoring in reducing the risk of PTLD in SOT recipients.
DOI: 10.1016/j.cmi.2015.02.002
PubMed: 25686696
Affiliations:
- Espagne, France, Italie, Suisse
- Alsace (région administrative), Canton de Vaud, Communauté de Madrid, Grand Est
- Lausanne, Madrid, Strasbourg
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.</title><author><name sortKey="San Juan, R" sort="San Juan, R" uniqKey="San Juan R" first="R" last="San-Juan">R. San-Juan</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain. Electronic address: rafasjg@yahoo.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Manuel, O" sort="Manuel, O" uniqKey="Manuel O" first="O" last="Manuel">O. Manuel</name><affiliation wicri:level="3"><nlm:affiliation>Transplantation Centre and Service of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Transplantation Centre and Service of Infectious Diseases, University Hospital of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Hirsch, H H" sort="Hirsch, H H" uniqKey="Hirsch H" first="H H" last="Hirsch">H H Hirsch</name><affiliation wicri:level="1"><nlm:affiliation>Transplantation & Clinical Virology, Department Biomedicine, Infectious Diseases & Hospital Epidemiology, University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Transplantation & Clinical Virology, Department Biomedicine, Infectious Diseases & Hospital Epidemiology, University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Fernandez Ruiz, M" sort="Fernandez Ruiz, M" uniqKey="Fernandez Ruiz M" first="M" last="Fernández-Ruiz">M. Fernández-Ruiz</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="L Pez Medrano, F" sort="L Pez Medrano, F" uniqKey="L Pez Medrano F" first="F" last="L Pez-Medrano">F. L Pez-Medrano</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Comoli, P" sort="Comoli, P" uniqKey="Comoli P" first="P" last="Comoli">P. Comoli</name><affiliation wicri:level="1"><nlm:affiliation>Pediatric Haematology-Oncology and Research Laboratories Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pediatric Haematology-Oncology and Research Laboratories Fondazione IRCCS Policlinico San Matteo, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Caillard, S" sort="Caillard, S" uniqKey="Caillard S" first="S" last="Caillard">S. Caillard</name><affiliation wicri:level="3"><nlm:affiliation>Nephrology and Transplantation Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Nephrology and Transplantation Department, Hôpitaux Universitaires de Strasbourg, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Grossi, P" sort="Grossi, P" uniqKey="Grossi P" first="P" last="Grossi">P. Grossi</name><affiliation wicri:level="1"><nlm:affiliation>National Centre for Transplantation, Infectious and Tropical Diseases Department, University of Insubria, Varese, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>National Centre for Transplantation, Infectious and Tropical Diseases Department, University of Insubria, Varese</wicri:regionArea><wicri:noRegion>Varese</wicri:noRegion></affiliation></author><author><name sortKey="Aguado, J M" sort="Aguado, J M" uniqKey="Aguado J" first="J M" last="Aguado">J M Aguado</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25686696</idno><idno type="pmid">25686696</idno><idno type="doi">10.1016/j.cmi.2015.02.002</idno><idno type="wicri:Area/Main/Corpus">000D04</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000D04</idno><idno type="wicri:Area/Main/Curation">000D04</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000D04</idno><idno type="wicri:Area/Main/Exploration">000D04</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.</title><author><name sortKey="San Juan, R" sort="San Juan, R" uniqKey="San Juan R" first="R" last="San-Juan">R. San-Juan</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain. Electronic address: rafasjg@yahoo.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Manuel, O" sort="Manuel, O" uniqKey="Manuel O" first="O" last="Manuel">O. Manuel</name><affiliation wicri:level="3"><nlm:affiliation>Transplantation Centre and Service of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Transplantation Centre and Service of Infectious Diseases, University Hospital of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Hirsch, H H" sort="Hirsch, H H" uniqKey="Hirsch H" first="H H" last="Hirsch">H H Hirsch</name><affiliation wicri:level="1"><nlm:affiliation>Transplantation & Clinical Virology, Department Biomedicine, Infectious Diseases & Hospital Epidemiology, University of Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Transplantation & Clinical Virology, Department Biomedicine, Infectious Diseases & Hospital Epidemiology, University of Basel, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Fernandez Ruiz, M" sort="Fernandez Ruiz, M" uniqKey="Fernandez Ruiz M" first="M" last="Fernández-Ruiz">M. Fernández-Ruiz</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="L Pez Medrano, F" sort="L Pez Medrano, F" uniqKey="L Pez Medrano F" first="F" last="L Pez-Medrano">F. L Pez-Medrano</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Comoli, P" sort="Comoli, P" uniqKey="Comoli P" first="P" last="Comoli">P. Comoli</name><affiliation wicri:level="1"><nlm:affiliation>Pediatric Haematology-Oncology and Research Laboratories Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pediatric Haematology-Oncology and Research Laboratories Fondazione IRCCS Policlinico San Matteo, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Caillard, S" sort="Caillard, S" uniqKey="Caillard S" first="S" last="Caillard">S. Caillard</name><affiliation wicri:level="3"><nlm:affiliation>Nephrology and Transplantation Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Nephrology and Transplantation Department, Hôpitaux Universitaires de Strasbourg, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Grossi, P" sort="Grossi, P" uniqKey="Grossi P" first="P" last="Grossi">P. Grossi</name><affiliation wicri:level="1"><nlm:affiliation>National Centre for Transplantation, Infectious and Tropical Diseases Department, University of Insubria, Varese, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>National Centre for Transplantation, Infectious and Tropical Diseases Department, University of Insubria, Varese</wicri:regionArea><wicri:noRegion>Varese</wicri:noRegion></affiliation></author><author><name sortKey="Aguado, J M" sort="Aguado, J M" uniqKey="Aguado J" first="J M" last="Aguado">J M Aguado</name><affiliation wicri:level="3"><nlm:affiliation>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author></analytic><series><title level="j">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</title><idno type="eISSN">1469-0691</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cross-Sectional Studies (MeSH)</term><term>Epstein-Barr Virus Infections (complications)</term><term>Epstein-Barr Virus Infections (diagnosis)</term><term>Epstein-Barr Virus Infections (prevention & control)</term><term>Epstein-Barr Virus Infections (therapy)</term><term>Europe (MeSH)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (administration & dosage)</term><term>Lymphoproliferative Disorders (diagnosis)</term><term>Lymphoproliferative Disorders (prevention & control)</term><term>Lymphoproliferative Disorders (therapy)</term><term>Organ Transplantation (MeSH)</term><term>Positron-Emission Tomography (MeSH)</term><term>Rituximab (administration & dosage)</term><term>Surveys and Questionnaires (MeSH)</term><term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term><term>Tomography, X-Ray Computed (MeSH)</term><term>Transplant Recipients (MeSH)</term><term>Viral Load (MeSH)</term><term>Viremia (diagnosis)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Charge virale (MeSH)</term><term>Enquêtes et questionnaires (MeSH)</term><term>Europe (MeSH)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (administration et posologie)</term><term>Infections à virus Epstein-Barr (complications)</term><term>Infections à virus Epstein-Barr (diagnostic)</term><term>Infections à virus Epstein-Barr (prévention et contrôle)</term><term>Infections à virus Epstein-Barr (thérapie)</term><term>Receveurs de transplantation (MeSH)</term><term>Rituximab (administration et posologie)</term><term>Syndromes lymphoprolifératifs (diagnostic)</term><term>Syndromes lymphoprolifératifs (prévention et contrôle)</term><term>Syndromes lymphoprolifératifs (thérapie)</term><term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term><term>Tomodensitométrie (MeSH)</term><term>Tomographie par émission de positons (MeSH)</term><term>Transplantation d'organe (MeSH)</term><term>Virémie (diagnostic)</term><term>Études transversales (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Immunosuppressive Agents</term><term>Rituximab</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>TOR Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Europe</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Immunosuppresseurs</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sérine-thréonine kinases TOR</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Epstein-Barr Virus Infections</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Epstein-Barr Virus Infections</term><term>Lymphoproliferative Disorders</term><term>Viremia</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à virus Epstein-Barr</term><term>Syndromes lymphoprolifératifs</term><term>Virémie</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Epstein-Barr Virus Infections</term><term>Lymphoproliferative Disorders</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à virus Epstein-Barr</term><term>Syndromes lymphoprolifératifs</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Epstein-Barr Virus Infections</term><term>Lymphoproliferative Disorders</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à virus Epstein-Barr</term><term>Syndromes lymphoprolifératifs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cross-Sectional Studies</term><term>Humans</term><term>Organ Transplantation</term><term>Positron-Emission Tomography</term><term>Surveys and Questionnaires</term><term>Tomography, X-Ray Computed</term><term>Transplant Recipients</term><term>Viral Load</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Charge virale</term><term>Enquêtes et questionnaires</term><term>Europe</term><term>Humains</term><term>Infections à virus Epstein-Barr</term><term>Receveurs de transplantation</term><term>Tomodensitométrie</term><term>Tomographie par émission de positons</term><term>Transplantation d'organe</term><term>Études transversales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There is limited clinical evidence on the utility of the monitoring of Epstein-Barr virus (EBV) DNAemia in the pre-emptive management of post-transplant lymphoproliferative disease (PTLD) in solid organ transplant (SOT) recipients. We investigated current preventive measures against EBV-related PTLD through a web-based questionnaire sent to 669 SOT programmes in 35 European countries. This study was performed on behalf of the ESGICH study group from the European Society of Clinical Microbiology and Infectious Diseases. A total of 71 SOT programmes from 15 European countries participated in the study. EBV serostatus of the recipient is routinely obtained in 69/71 centres (97%) and 64 (90%) have access to EBV DNAemia assays. EBV monitoring is routinely used in 85.9% of the programmes and 77.4% reported performing pre-emptive treatment for patients with significant EBV DNAemia levels. Pre-emptive treatment for EBV DNAemia included reduction of immunosuppression in 50.9%, switch to mammalian target of rapamycin inhibitors in 30.9%, and use of rituximab in 14.5% of programmes. Imaging by whole-body 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) is used in 60.9% of centres to rule out PTLD and complemented computer tomography is used in 50%. In 10.9% of centres, FDG-PET is included in the first-line diagnostic workup in patients with high-risk EBV DNAemia. Despite the lack of definitive evidence, EBV load measurements are frequently used in Europe to guide diagnostic workup and pre-emptive reduction of immunosuppression. We need prospective and controlled studies to define the impact of EBV monitoring in reducing the risk of PTLD in SOT recipients. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25686696</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2015</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0691</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</Title><ISOAbbreviation>Clin Microbiol Infect</ISOAbbreviation></Journal><ArticleTitle>Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.</ArticleTitle><Pagination><MedlinePgn>604.e1-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cmi.2015.02.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1198-743X(15)00288-8</ELocationID><Abstract><AbstractText>There is limited clinical evidence on the utility of the monitoring of Epstein-Barr virus (EBV) DNAemia in the pre-emptive management of post-transplant lymphoproliferative disease (PTLD) in solid organ transplant (SOT) recipients. We investigated current preventive measures against EBV-related PTLD through a web-based questionnaire sent to 669 SOT programmes in 35 European countries. This study was performed on behalf of the ESGICH study group from the European Society of Clinical Microbiology and Infectious Diseases. A total of 71 SOT programmes from 15 European countries participated in the study. EBV serostatus of the recipient is routinely obtained in 69/71 centres (97%) and 64 (90%) have access to EBV DNAemia assays. EBV monitoring is routinely used in 85.9% of the programmes and 77.4% reported performing pre-emptive treatment for patients with significant EBV DNAemia levels. Pre-emptive treatment for EBV DNAemia included reduction of immunosuppression in 50.9%, switch to mammalian target of rapamycin inhibitors in 30.9%, and use of rituximab in 14.5% of programmes. Imaging by whole-body 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) is used in 60.9% of centres to rule out PTLD and complemented computer tomography is used in 50%. In 10.9% of centres, FDG-PET is included in the first-line diagnostic workup in patients with high-risk EBV DNAemia. Despite the lack of definitive evidence, EBV load measurements are frequently used in Europe to guide diagnostic workup and pre-emptive reduction of immunosuppression. We need prospective and controlled studies to define the impact of EBV monitoring in reducing the risk of PTLD in SOT recipients. </AbstractText><CopyrightInformation>Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>San-Juan</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain. Electronic address: rafasjg@yahoo.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manuel</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Transplantation Centre and Service of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirsch</LastName><ForeName>H H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Transplantation & Clinical Virology, Department Biomedicine, Infectious Diseases & Hospital Epidemiology, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández-Ruiz</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Medrano</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comoli</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pediatric Haematology-Oncology and Research Laboratories Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caillard</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nephrology and Transplantation Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossi</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Centre for Transplantation, Infectious and Tropical Diseases Department, University of Insubria, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguado</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Instituto de Investigación Hospital 12 de Octubre (i+12), University Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ESGICH PTLD Survey Study Group,</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>European Study Group of Infections in Compromised Hosts (ESGICH) from the European Society of Microbiology and Infectious Diseases (ESCMID)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Microbiol Infect</MedlineTA><NlmUniqueID>9516420</NlmUniqueID><ISSNLinking>1198-743X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="N">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008232" MajorTopicYN="N">Lymphoproliferative Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016377" MajorTopicYN="Y">Organ Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066027" MajorTopicYN="Y">Transplant Recipients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014766" MajorTopicYN="N">Viremia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epstein–Barr virus</Keyword><Keyword MajorTopicYN="N">Europe</Keyword><Keyword MajorTopicYN="N">post-transplant lymphoproliferative disease</Keyword><Keyword MajorTopicYN="N">pre-emptive treatment</Keyword><Keyword MajorTopicYN="N">survey</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Álamo-Martínez</LastName><ForeName>José María</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anaya</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anttila</LastName><ForeName>Veli-Jukka</ForeName><Initials>VJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnol</LastName><ForeName>Miha</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avolio</LastName><ForeName>Alfonso W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baccarani</LastName><ForeName>Umberto</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castello</LastName><ForeName>Isabel Beneyto</ForeName><Initials>IB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boletis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonofiglio</LastName><ForeName>Renzo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viamigliori</LastName><ForeName>Annunziata</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bressollette</LastName><ForeName>Celine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brockmann</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caillard</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pulido</LastName><ForeName>Jorge Calvo</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Catalán</LastName><ForeName>Pilar</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christiansen</LastName><ForeName>Claus</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cofan</LastName><ForeName>Frederic</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cordero</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leiro</LastName><ForeName>Marisa Crespo</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dantal</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'armini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'armini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delgado</LastName><ForeName>Juan F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dello Strologo</LastName><ForeName>Luca</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gesu</LastName><ForeName>Bambino</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Raimondo</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dierickx</LastName><ForeName>Daan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eis- Hübinger</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kremer</LastName><ForeName>Samira Faf</ForeName><Initials>SF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faggian</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fariñas</LastName><ForeName>María Carmen</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Folgueira</LastName><ForeName>Maria Dolores</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fontana</LastName><ForeName>Iris</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franco</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furian</LastName><ForeName>Lucrezia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garzoni</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghirardo</LastName><ForeName>Giulia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ginevri</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grinyó</LastName><ForeName>Josep</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossi</LastName><ForeName>Paolo Antonio</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupte</LastName><ForeName>Girish</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hansson</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Helanterä</LastName><ForeName>Ilkka</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herrero</LastName><ForeName>Jose Ignacio</ForeName><Initials>JI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirsch</LastName><ForeName>Hans H</ForeName><Initials>HH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hobin</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Dieter</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jan</LastName><ForeName>Lerut</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jarque</LastName><ForeName>Isidro</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jespersen</LastName><ForeName>Bente</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaczmarek</LastName><ForeName>Ingo</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klin</LastName><ForeName>Grosshadern</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kevin</LastName><ForeName>Pilarczyk</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koneth</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kovac</LastName><ForeName>Damjan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacaille</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lautenschlager</LastName><ForeName>Irmeli</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Len</LastName><ForeName>Oscar</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lladó</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loy</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manuel</LastName><ForeName>Oriol</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maeso</LastName><ForeName>Maria Angeles Marcos</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marianne</LastName><ForeName>Leruez-Ville</ForeName><Initials>LV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsh</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meylan</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miñambres</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montejo</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mueller</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muñoz</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nadalin</LastName><ForeName>Silvio</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kamar</LastName><ForeName>Nassim</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicolas</LastName><ForeName>Blin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olivier</LastName><ForeName>Detry</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palomo</LastName><ForeName>Jesus</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pascual</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peter</LastName><ForeName>Jaksch</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierre</LastName><ForeName>Frange</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Portero</LastName><ForeName>M Francisca</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Provot</LastName><ForeName>Francois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boluda</LastName><ForeName>Esther Ramos</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Regalia</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reina</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reuter</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ricart</LastName><ForeName>M José</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>García</LastName><ForeName>Minerva Rodríguez</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rollag</LastName><ForeName>Halvor</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russo</LastName><ForeName>Francesco Paolo</ForeName><Initials>FP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabé</LastName><ForeName>Núria</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salcedo</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santambrogio</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeman</LastName><ForeName>Tomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serra</LastName><ForeName>Nuria</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sgarabotto</LastName><ForeName>Dino</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simonek</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thierry</LastName><ForeName>Yandza</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomsen</LastName><ForeName>Marianne Kragh</ForeName><Initials>MK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tihic</LastName><ForeName>Nijaz</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torre-Cisneros</LastName><ForeName>Julian</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Travi</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tulissi</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moal</LastName><ForeName>Valérie</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veroux</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santandreu</LastName><ForeName>Ana Vila</ForeName><Initials>AV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vizzini</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zibar</LastName><ForeName>Lada</ForeName><Initials>L</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>02</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25686696</ArticleId><ArticleId IdType="pii">S1198-743X(15)00288-8</ArticleId><ArticleId IdType="doi">10.1016/j.cmi.2015.02.002</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li><li>France</li><li>Italie</li><li>Suisse</li></country><region><li>Alsace (région administrative)</li><li>Canton de Vaud</li><li>Communauté de Madrid</li><li>Grand Est</li></region><settlement><li>Lausanne</li><li>Madrid</li><li>Strasbourg</li></settlement></list><tree><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="San Juan, R" sort="San Juan, R" uniqKey="San Juan R" first="R" last="San-Juan">R. San-Juan</name></region><name sortKey="Aguado, J M" sort="Aguado, J M" uniqKey="Aguado J" first="J M" last="Aguado">J M Aguado</name><name sortKey="Fernandez Ruiz, M" sort="Fernandez Ruiz, M" uniqKey="Fernandez Ruiz M" first="M" last="Fernández-Ruiz">M. Fernández-Ruiz</name><name sortKey="L Pez Medrano, F" sort="L Pez Medrano, F" uniqKey="L Pez Medrano F" first="F" last="L Pez-Medrano">F. L Pez-Medrano</name></country><country name="Suisse"><region name="Canton de Vaud"><name sortKey="Manuel, O" sort="Manuel, O" uniqKey="Manuel O" first="O" last="Manuel">O. Manuel</name></region><name sortKey="Hirsch, H H" sort="Hirsch, H H" uniqKey="Hirsch H" first="H H" last="Hirsch">H H Hirsch</name></country><country name="Italie"><noRegion><name sortKey="Comoli, P" sort="Comoli, P" uniqKey="Comoli P" first="P" last="Comoli">P. Comoli</name></noRegion><name sortKey="Grossi, P" sort="Grossi, P" uniqKey="Grossi P" first="P" last="Grossi">P. Grossi</name></country><country name="France"><region name="Grand Est"><name sortKey="Caillard, S" sort="Caillard, S" uniqKey="Caillard S" first="S" last="Caillard">S. Caillard</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25686696
|texte= Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25686696" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |